Evofem Biosciences, Inc. Common Stock
EVFM
EVFM was delisted on the 10th of August, 2022.
51 hedge funds and large institutions have $195M invested in Evofem Biosciences, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 12 increasing their positions, 17 reducing their positions, and 2 closing their positions.
450% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 2
21% more funds holding
Funds holding: 42 → 51 (+9)
4% more capital invested
Capital invested by funds: $188M → $195M (+$6.72M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
29% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$38.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.12M |
| 3 |
DC
Davenport & Co
Richmond,
Virginia
|
+$237K |
| 4 |
Squarepoint
New York
|
+$188K |
| 5 |
OC
Oppenheimer & Co
New York
|
+$165K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Schroder Investment Management Group
London,
United Kingdom
|
-$896K |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$723K |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$472K |
| 4 |
Renaissance Technologies
New York
|
-$177K |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$131K |
EVFM Hedge Fund Activity: Q1 2020 in Review
51 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Evofem Biosciences, Inc. Common Stock (EVFM) for Q1 2020, worth a combined $195M — up 3.6% from $188M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new EVFM positions and 2 closed out — a net gain of 9 holders — while 12 added to existing stakes and 17 trimmed.
The largest buyer was BlackRock, adding an estimated $38.3M. The largest seller was Schroder Investment Management Group, cutting an estimated $896K.
- 51 institutional investors held Evofem Biosciences, Inc. Common Stock (EVFM) as of Q1 2020, up from 42 in Q4 2019.
- Funds reported $195M of Evofem Biosciences, Inc. Common Stock stock for Q1 2020, up 3.6% quarter-over-quarter.
- 11 funds opened new Evofem Biosciences, Inc. Common Stock positions in Q1 2020 and 2 closed out, a net change of +9 holders.
- The largest Evofem Biosciences, Inc. Common Stock buyer in Q1 2020 was BlackRock, an estimated $38.3M added.
- The largest Evofem Biosciences, Inc. Common Stock seller in Q1 2020 was Schroder Investment Management Group, an estimated $896K sold.
Based on aggregated 13F filings for Q1 2020.